Epigenomics · 2012 · 45 citations · 103 references
Life SciencesOncologyPharmacologyApoptosisAutophagyCancer PharmacologyAutophagy In CancerAutophagy PharmacologyAutophagy RegulationCell-cycle DysregulationEnzyme InhibitionAnticancer ActivityApoptosis InductionCutaneous T-cell Lymphoma TreatmentEnzymesHistone AcetylationHistone DeacetylasesProteasome Inhibitor TherapyProteasome Inhibitors
Romidepsin (Istodax(®), depsipeptide, FR901228, FK228, NSC 630176) is a cyclic peptide, broad-spectrum, potent histone deacetylase inhibitor, with activity mainly against class I histone deacetylase enzymes. In this article, we give an overview of the putative modes of action, such as effects on gene expression, cell cycle regulation, apoptosis induction, DNA repair, protein acetylation and induction of autophagy. Romidepsin has mainly been developed as a therapy for hematologic malignancies and is approved by the US FDA for the treatment of cutaneous T-cell lymphomas. This report outlines the laboratory and clinical development of the compound as a single agent that has more recently been evaluated in combination with other anticancer therapeutics, such as proteasome inhibitors.
103
Autophagy in the Pathogenesis of Disease
Beth Levine, Guido Kroemer · Cell · 2008 · 7K citations · Full text
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary, Chanchal Kumar, Florian Gnad et al. · Science · 2009 · 4K citations · Full text
Victoria M. Richon, Todd W. Sandhoff, Richard A. Rifkind et al. · Proceedings of the National Academy of Sciences · 2000 · 1.1K citations · Full text
Roy A. Frye · Biochemical and Biophysical Research Communications · 1999 · 805 citations